Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer
Wennuan Liu(Wake Forest University), G. Steven Bova(Prostate Cancer Research), Jeanne Kowalski(The University of Texas at Austin), Mauno Vihinen(Lund University), William G. Nelson(Johns Hopkins University), Charles M. Ewing(Johns Hopkins University), Sofia Khan(University of Helsinki), William B. Isaacs(Unknown), Guoqiang Yu(University of Kentucky), Jun Luo(Johns Hopkins University), Tapio Visakorpi(Tampere University Hospital), Sari Laitinen(Tampere University Hospital), Srinivasan Yegnasubramanian(Johns Hopkins University), Yue Wang(Virginia Tech), Li Chen(Harvard University), Michael A. Carducci(Sidney Kimmel Comprehensive Cancer Center), Jianfeng Xu(NorthShore University HealthSystem), Mario A. Eisenberger(Johns Hopkins University)
Cited by 666
Related Papers
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k
The evolutionary history of lethal metastatic prostate cancer
|Nature|2015|1.4k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED Trial
|Journal of Clinical Oncology|2018|1.1k